[
  {
    "ts": null,
    "headline": "The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District",
    "summary": "NEWTON, Mass., August 07, 2025--The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgage financing with a weighted-average interest rate of 5.5957%, secured by Vertex Pharmaceuticals Incorporated’s (\"Vertex\") 1.1 million square foot headquarters at 50 Northern Avenue and 11 Fan Pier Boulevard in the Boston Seaport district. The financing proceeds will primarily be used to repay the exist",
    "url": "https://finnhub.io/api/news?id=1434d4ed627beb6aec42feba5cd8f3e7b8044546888f05f9a6ce5741f6f7dbcc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754597700,
      "headline": "The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District",
      "id": 136267097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "NEWTON, Mass., August 07, 2025--The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgage financing with a weighted-average interest rate of 5.5957%, secured by Vertex Pharmaceuticals Incorporated’s (\"Vertex\") 1.1 million square foot headquarters at 50 Northern Avenue and 11 Fan Pier Boulevard in the Boston Seaport district. The financing proceeds will primarily be used to repay the exist",
      "url": "https://finnhub.io/api/news?id=1434d4ed627beb6aec42feba5cd8f3e7b8044546888f05f9a6ce5741f6f7dbcc"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=88b4cbe02095c2b7e9780dc306ee07bceefe67382dd58649541f6cbc2a45f269",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584800,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 136299873,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=88b4cbe02095c2b7e9780dc306ee07bceefe67382dd58649541f6cbc2a45f269"
    }
  },
  {
    "ts": null,
    "headline": "The Best Stocks to Invest $1,000 In Right Now",
    "summary": "Market volatility could increase in the months ahead, but these stocks should hold up well.",
    "url": "https://finnhub.io/api/news?id=91fcec607228b140d36a4ebce98f55f8c61082fe543a8c41328ea2613da326bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754556000,
      "headline": "The Best Stocks to Invest $1,000 In Right Now",
      "id": 136246247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Market volatility could increase in the months ahead, but these stocks should hold up well.",
      "url": "https://finnhub.io/api/news?id=91fcec607228b140d36a4ebce98f55f8c61082fe543a8c41328ea2613da326bc"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million",
    "summary": "Vertex Pharmaceuticals (VRTX) recently announced strong financial results with Q2 2025 revenue increasing to $2,965 million from $2,646 million in Q2 2024, and net income turning positive. Despite this, the share price fell 10.23% over the last quarter. The positive earnings were in juxtaposition to the halted development of VX-993 following disappointing study results and the impact of being removed from Russell indexes. Meanwhile, broader market gains were influenced by rising stocks in...",
    "url": "https://finnhub.io/api/news?id=de982ae5ca637da9ba88fed81445e2ad5dd303f232860fed6a44e53d930d2043",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754544700,
      "headline": "Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million",
      "id": 136246405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) recently announced strong financial results with Q2 2025 revenue increasing to $2,965 million from $2,646 million in Q2 2024, and net income turning positive. Despite this, the share price fell 10.23% over the last quarter. The positive earnings were in juxtaposition to the halted development of VX-993 following disappointing study results and the impact of being removed from Russell indexes. Meanwhile, broader market gains were influenced by rising stocks in...",
      "url": "https://finnhub.io/api/news?id=de982ae5ca637da9ba88fed81445e2ad5dd303f232860fed6a44e53d930d2043"
    }
  }
]